Back to search results
NCT07634939

Liver Micro Flow - MRI

Not Yet Recruiting
Not specifiedAges 7+Observational
University of Wisconsin, Madison
~110 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Novel MRI SoftwareEnsure Plus Nutrition Shake

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Test-retest repeatability of IVIM parameters: Perfusion Fraction
Measured over data collected over one hour during one study visit
+2 more outcomes measured

Conditions

Liver Diseases

Explore related trials

Chronic Liver DiseaseCirrhosisHepatic SteatosisLiver FibrosisNonalcoholic Fatty Liver DiseasePortal Hypertension

NCT07634939

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Wisconsin

    Madison, Wisconsinno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Diego Hernando, PhD · PRINCIPAL_INVESTIGATOR · UW School of Medicine and Public Health

Who to contact

Radiology Study
[email protected]
608-282-8349
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 7 years or older
Willing and able to complete study procedures
Age 7 years or older
Willing and able to complete study procedures
Clinical evidence of MASLD, MASH, cirrhosis or liver fibrosis
Age 7 years or older
Willing and able to complete study procedures
Known or suspected liver steatosis, steatohepatitis, fibrosis, cirrhosis, or portal hypertension, based on clinical imaging from the previous 6 months or histology over the previous 12 months.
At least N=50 will be selected based on having a clinically indicated liver biopsy
If taking beta blocker medication, willing to temporarily discontinue the medication for three days prior to the research visit after providing informed consent and in consultation with their treating physician.

Exclusion

Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
Received ferumoxytol injection within previous one year (clinical or research)
Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:
The person has their own prescription for the medication.
The informed consent process is conducted prior to the self-administration of this medication
They come to the research visit with a driver
Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
Received ferumoxytol injection within previous one year (clinical or research)
Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:
The person has their own prescription for the medication.
The informed consent process is conducted prior to the self-administration of this medication
They come to the research visit with a driver
Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)
Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)
Received ferumoxytol injection within previous one year (clinical or research)
Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:
The person has their own prescription for the medication.
The informed consent process is conducted prior to the self-administration of this medication
They come to the research visit with a driver

What this trial measures

  • Test-retest repeatability of IVIM parameters: Perfusion Fractiondata collected over one hour during one study visit

    Test-retest repeatability of IVIM parameters will be acquired during a single study visit, summarized using repeatability coefficients and Bland-Altman analysis.

  • Test-retest repeatability of IVIM parameters: Blood Velocity Standard Deviationdata collected over one hour during one study visit

    Test-retest repeatability of IVIM parameters will be acquired during a single study visit, summarized using repeatability coefficients and Bland-Altman analysis.

  • Test-retest repeatability of IVIM parameters: Diffusion Coefficientdata collected over one hour during one study visit

    Test-retest repeatability of IVIM parameters will be acquired during a single study visit, summarized using repeatability coefficients and Bland-Altman analysis.